Core Viewpoint - The recent surge in Via Biotechnology's stock price reflects growing confidence in the AI drug development sector, with significant contracts being signed and a shift from conceptual to practical applications of AI in pharmaceuticals [1] Company Summary - Via Biotechnology's stock rose over 5%, currently trading at 2.59 HKD with a transaction volume of 20.26 million HKD [1] - The company has been involved in AI drug development for five years, with AI-related orders now accounting for 12% of new contracts, showing a growth trend [1] - Via Biotechnology's CRO business focuses on early-stage drug discovery, integrating AI to enhance research efficiency and success rates [1] - The AIDD platform has participated in the development of 175 projects, with AI-enabled CRO services contributing 10% to total revenue [1] Industry Summary - GF Securities reports a recent increase in global AI drug development contracts, indicating a clearer recognition of the strategic value of AI in pharmaceuticals by major companies [1] - The industry is transitioning from the conceptual phase of AI drug development to tangible applications and platform integration [1] - The trend of accelerated development in the AIDD sector is expected to become more pronounced by mid-next year [1]
港股异动 | 维亚生物(01873)再涨超5% AIDD行业加速发展 公司前瞻布局AI制药领域